COMy 2022 | The European Myeloma Network: upcoming clinical trials
Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands, shares some insights into the European Myeloma Network (EMN) and upcoming clinical trials, drawing focus on one trial which will be comparing the use of CAR-T therapy versus high-dose melphalan and autologous transplantation in the frontline setting. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Transcript (edited for clarity)
Hello. My name is Pieter Sonneveld, I am a hematologist in Rotterdam, The Netherlands. I’m also chair of the European Myeloma Network, which is a platform for organizing clinical trials between many countries, mainly in Europe, but also Australia and other countries. So the European Myeloma Network is performing several trials and I would specifically like to mention one, which is a new trial in newly diagnosed transplant-eligible patients with multiple myeloma that will compare CAR-T cell therapy in the frontline setting head to head with high-dose melphalan and autologous transplant...
Hello. My name is Pieter Sonneveld, I am a hematologist in Rotterdam, The Netherlands. I’m also chair of the European Myeloma Network, which is a platform for organizing clinical trials between many countries, mainly in Europe, but also Australia and other countries. So the European Myeloma Network is performing several trials and I would specifically like to mention one, which is a new trial in newly diagnosed transplant-eligible patients with multiple myeloma that will compare CAR-T cell therapy in the frontline setting head to head with high-dose melphalan and autologous transplant. And this will be a landmark trial, I expect with participation of many countries around the world, sponsored by EMN, where we in collaboration with Janssen, we will really explore the value of CAR-T cell therapy in an early phase of the disease, where hopefully, the results will be good and maybe also in the end will be a step towards cure in multiple myeloma.
Read more...
